TY  - GEN
AU  - Kalinsky,K
AU  - Sparano,J A
AU  - Zhong,X
AU  - Andreopoulou,E
AU  - Taback,B
AU  - Wiechmann,L
AU  - Feldman,S M
AU  - Ananthakrishnan,P
AU  - Ahmad,A
AU  - Cremers,S
AU  - Sireci,A N
AU  - Cross,J R
AU  - Marks,D K
AU  - Mundi,P
AU  - Connolly,E
AU  - Crew,K D
AU  - Maurer,M A
AU  - Hibshoosh,H
AU  - Lee,S
AU  - Hershman,D L
TI  - Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial
SN  - 1699-3055
PY  - 2019///0520
KW  - Adult
KW  - Aged
KW  - Biomarkers
KW  - blood
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Carcinoma, Ductal, Breast
KW  - Drug Evaluation
KW  - Female
KW  - Heterocyclic Compounds, 3-Ring
KW  - adverse effects
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - New York
KW  - Phosphatidylinositol 3-Kinases
KW  - metabolism
KW  - Proto-Oncogene Proteins c-akt
KW  - antagonists & inhibitors
KW  - Signal Transduction
KW  - drug effects
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study
UR  - https://doi.org/10.1007/s12094-018-1888-2
ER  -